Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
October 15, 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
October 03, 2024 07:00 ET
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Oct. 03, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 01, 2024 07:30 ET
|
Abeona Therapeutics Inc.
CLEVELAND, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...
Safety Shot Spins Off Caring Brands Business with Plans to Issue a Dividend to Shareholders
September 26, 2024 09:15 ET
|
Safety Shot, Inc.
The Company is Divesting its Wellness Unit to Create Value for Shareholders and to Focus on Commercialization of its Safety Shot Dietary Supplement JUPITER, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) --...
ADR Ratio Change
September 19, 2024 16:30 ET
|
Biodexa Pharmaceuticals PLC
September 19, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical...
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging
September 18, 2024 11:07 ET
|
Io Therapeutics, Inc.
Io Therapeutics, Inc., presented on IRX4204 for treatment of brain aging, at the FASEB Conference on Cellular and Molecular Mechanisms of Brain Aging
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
September 16, 2024 06:30 ET
|
Cybrexa Therapeutics
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
Gene Therapy Market Set for 19% CAGR Surge, Reaching USD 38.34 Billion by 2031 | SkyQuest Technology
September 12, 2024 09:30 ET
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford, USA, Sept. 12, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the Global Gene Therapy Market will reach a value of USD 38.34 Billion by 2031, with a CAGR of 19% during the forecast period...
Harvey Homan to Highlight MetasTx’s Game-Changing Approach to Cancer Treatment at PA Life Science Futures
September 12, 2024 06:58 ET
|
MetasTx LLC
MetasTx aims to revolutionize cancer treatment by targeting p21-activated kinase (PAK-1), a critical driver of metastasis in solid tumors.
Gamification Mobile Application in Healthcare Market is Expected to Hit US$ 31,168.1 Million by 2034 | Fact.MR Report
September 12, 2024 06:00 ET
|
FACT.MR
Rockville, MD, Sept. 12, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global gamification mobile application in healthcare market is...